Basic & Clinical Cancer Research is a peer-reviewed, open-access journal that aims to publish the highest quality articles on all aspects of cancer research, including research findings of pathophysiology, prevention, diagnosis and treatment of cancers, and technical evaluations and serves as a discussion forum for cancer scientists.

 

This Journal is indexed in:

Dimensions

Directory of Open Access Journal (DOAJ)

EBSCO

Google Scholar

Index Copernicus

Islamic World Science Citation Center (ISC)

ProQuest   

Scientific Information Database (SID)

Ulrichsweb

             

 

Current Issue

Vol 13 No 1 (2021)

Original Articles

  • XML | PDF | downloads: 22 | views: 32 | pages: 1-8
    Background: COVID-19 could cause severe complications in those with pre-existing conditions such as cancer. Here, we aimed to assess the outcome of COVID-19 in hospitalized patients with a history of cancer. Methods: In this retrospective cohort study, we extracted patients' records with any cancer history out of hospitalized patients with COVID-19. Our patients were admitted between February 20th up to July 15th. The primary outcome was death, and the secondary outcomes were overall survival, COVID-19 specific mortality, admission to intensive care unit (ICU) and hospital stay. A group of individuals was selected out of the COVID-19 cohort without cancer history and matched for age, gender, and pre-existing conditions. We utilized univariate and multivariate logistic regression to analyze the association of studied variables and primary outcomes. Results: We identified 46 patients with cancer and COVID-19. The median age was 63, and 54.3% were male. According to the univariate logistic regression analysis, the death was 5.3 (CI95%: 1.75-15.85) times more probable in the cancer patients versus controls (p=0.003). The multivariate analysis adjusted for having cancer and sex, age, and having any comorbidity showed this figure was 5.5 (CI95%:1.8-16.8) (p=0.003). The 30- and 90-day COVID-19 specific mortality was 30% (CI95%:17-43) and 33% (CI95%: 20-46), respectively. Conclusion: Patients with COVID-19 who have a history of cancer have a considerably higher risk of death irrespective of age, gender, and other pre-existing conditions. A group of cancer patients needs the most vigorous care, those with advanced cancers and concurrent bacterial infections.
  • XML | PDF | downloads: 12 | views: 11 | pages: 9-20
    Background: We evaluated the role of early diffusion weighted imaging (DWI) in predicting response to TACE in patients with HCC and compare the results with contrast enhanced magnetic resonance imaging. METHODS: 24 patients with documented HCC were taken up for TACE after a pre-procedural contrast CT and MRI. Post procedural DWI was taken on day 5-7 and the mean ADC values were documented and compared to pre procedural values. The change in ADC values was grouped into 4 categories: group 1- <25%, group 2 26-50%, group 3- 51-75% and group 4- >75%. The increase in ADC values signifying response was correlated with 5 week CEMRI scan and a threshold ADC increase signifying response in majority of the cases was calculated. RESULTS: The mean ADC of the lesions changed from 1.21× 10-3 (pre TACE) to 2.02× 10-3 mm2/sec (post TACE) [p<0.001]. Taking CE MRI as gold standard, DWI imaging had a sensitivity of 80%, specificity of 94.7% with a positive predictive value of 80%, negative predictive value of 94.7% and overall accuracy of 91.7%. Complete response was seen in19 (79%) and incomplete in 5 (21%) patients in our study. The change in ADC was significantly higher in responders (884.15 ± 161.60) as compared to non responders (564.80 ± 221.05) [p =0.001]. CONCLUSION: Early DWI after TACE can predict response of a HCC lesion to chemoembolization. The change in ADC values can earmark responders from non-responders. Early DWI results are concordant with CEMRI results in most of the cases. DWI can act as a substitute to CEMRI when contrast administration is not advised.
  • XML | PDF | downloads: 13 | views: 7 | pages: 21-29
    Abstract   This study investigated the possible role of Genistein as a combination with Imatinib in controlling leukemia cell lines proliferation. Three cell lines K562, Kcl22 and CCRF were cultured in in vitro environment and analyzed for MTT, LDH, apoptosis and cycle cell gene expression in the presence of different dosages of Imatinib and Genistein in combination or separately. Data has shown a decrease in proliferation and an increase in apoptosis activity during combination treatment. LDH assay has shown no additional toxicity due to Genistein consumption in combination therapy. Analysis the expression of responsible genes for cell cycle demonstrated that G1 and G2 regulation in combination treatment. Altogether, this study suggests that the combination treatment of Imatinib and Genistein for treating leukemia cells resistant to Imatinib, can increase the efficiency of treatment.
View All Issues